natgillin/translations-raw huggingface dataset:
by selectively protecting the 5'-hydroxy group in an intermediate 3a yielding an intermediate 3b, which in turn is esterified to an intermediate 3c, followed by a uracil to cytosine conversion to an intermediate 3d; deprotecting the latter to the 3'-monoester I-c; or by esterifying the 5'-hydroxy in 1-c to a compound I-d; or by selectively esterifying the 5'-hydroxy group in an intermediate 3 a thus introducing a group R4a resulting in an intermediate 3e, and intermediate 3e is subsequently esterified with a different acid thereby introducing a group R3a, yielding a di-ester intermediate 3f, which is submitted to a uracil to cytosine conversion, to yield a compound I-d: 
pomoću selektivne zaštite 5'-hidroksi skupine u intermedijer 3a čime se dobiva intermedijer 3b, koji se zatim esterificira u intermedijer 3c, te se zatim provodi konverzija uracila u citozin u intermedijer 3d; te se za ovaj posljednji provodi uklanjanje zaštite u 3'-monoester I-c; ili pomoću esterifikacije iz 5'-hidroksi u I-c do spoja I-d; ili pomoću selektivne esterifikacije 5'-hidroksi skupine u intermedijer 3a, te se stoga uvodi skupina R4a što dovodi do intermedijera 3e,a intermedijer 3e se naknadno esterificira sa različitom kiselinom te se uvodi skupina R3a, što dovodi do di-ester intermedijera 3f, koji se podvrgava konverziji uracila u citozin, da se dobije spoj I-d: [image]
Ar1 and Ar2 are substituted or unsubstituted phenyl or het; 
Ar1 i Ar2 su supstituirani ili nesupstituirani fenil ili het;
A compound of formula (IV) as claimed in claim 1, wherein D is C(O), and R4 is isopropyl, t-butyl, cyclopentyl, or cyclohexyl; 
Spojevi formule (IV) prema zahtjevu 1, naznačeni time, da D je C(O), a R4 je izopropil, t-butil, ciklopentil ili cikloheksil.
A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of formula (IV) according to any one of claims 1 to 8. 
Farmaceutski sastav, naznačen time, da obuhvaća farmaceutski prihvatljiv nosač i terapeutski učinkovitu količinu spoja formule (IV) prema bilo kojem od zahtjeva 1 do 8.
Process as claimed in claim 7, wherein the reinforcing material is a non-woven polyester. 
Postupak kako je prijavljen u patentnom zahtjevu 7, naznačen time da je materijal za pojačavanje netkani poliester.
Use according to any one of claims 1 to 5 wherein said non-naturally occurring molecule is a polypeptide and is encoded by a nucleotide sequence present on a recombinant vector and which, upon introduction into a cell or organism, produces said polypeptide in said cell or organism. 
Molekula za uporabu prema bilo kojem od zahtjeva 1 do 5 naznačena time da navedena molekula je polipeptid, te je kodirana pomoću nukleotidne sekvence koja se nalazi na rekombinantnom vektoru i koji, nakon transformacije u stanicu ili organizam, proizvodi navedeni polipeptid u navedenoj stanici ili organizmu.
The method of Claim 1 wherein the environment is soil and a liquid composition comprising the mixture is applied to the soil as a soil drench. 
Metoda iz bilo kojeg od patentnih zahtjeva 1 do 3, gdje je okoliš tlo i tekući se sastav koji obuhvaća smjesu primjenjuje na tlo kao kvašenje tla.
Use of a salt according to any of claims 1-8 in the preparation of a medicament for the treatment of a disease selected from the group consisting of a disease involving psychotic symptoms, anxiety disorders, affective disorders including depression, sleep disturbances, migraine, neuroleptic-induced parkinsonism, or abuse disorders, e.g . 
Uporaba spoja formule (Spoj I, trans-1-((1R,3S)-6-klor-3-fenilindan-1-il)-3,3-dimetilpiperazin) [image] ili njegove soli u pripremi lijeka za liječenje bolesti izabrane iz grupe koja obuhvaća bolest koja uključuje psihotične simptome, shizofreniju, anksiozne poremećaje, afektivne poremećaje, afektivne poremećaje koji uključuju depresiju, poremećaje spavanja, migrenu, neuroleptički-inducirani parkinsonizam, i poremećaje ovisnosti npr.
cocaine abuse, nicotine abuse, or alcohol abuse. 
ovisnost o kokainu, nikotinu ili alkoholu.
Use of a salt according to any of claims 1-8 in the preparation of a medicament for the treatment of a disease selected from the group consisting of Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Brief Psychotic Disorder, Shared Psychotic Disorder, and mania in bipolar disorder. 
Uporaba spoja formule (Spoj I, trans-1-((1R,3S)-6-klor-3-fenilindan-1-il)-3,3-dimetilpiperazin) [image] ili njegove soli u pripremi lijeka za liječenje bolesti izabrane iz grupe koja obuhvaća shizofreniju, shizofrenoformni poremećaj, shizoafektivni poremećaj, deluzijski poremećaj, kratki psihotični poremećaj, podijeljeni psihotični poremećaj te maniju i bipolarni poremećaj.
a soluble Sp35 polypeptide that lacks an Sp35 transmembrane domain; 
topljivi Sp35 polipeptid kojem nedostaje Sp35 transmembranska domena i Sp35 citoplazmatična domena;
Use of an Sp35 (LINGO-1) antagonist selected from the group consisting of: 
Antagonist Sp35 (LINGO-1) izabran iz grupe koju čine:
A pharmaceutical composition comprising an effective amount of the compound of claim 1 or 2 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. 
Farmaceutska kompozicija koja sadrži efikasnu količinu spoja prema patentnom zahtjevu 1 ili 2 ili njegove farmaceutski prihvatljive soli i farmaceutski prihvatljiv nosač.
The compound for use according to claim 5 wherein the therapy is the prevention or treatment of HCV infection. 
Spoj za uporabu prema patentnom zahtjevu 5, pri čemu je terapija prevencija ili liječenje HCV infekcije.
Use of a compound according to claim 1 or 2 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for the prevention or treatment of HCV infection. 
Uporaba spoja prema patentnom zahtjevu 1 ili 2 ili njegove farmaceutski prihvatljive soli u pripremi lijeka za prevenciju ili liječenje HCV infekcije.
wherein "het" is a 5-7 membered heterocyclic ring containing 1- 4 heteroatoms selected from N, O and S, or an 8-12 membered fused ring system including at least one 5-7 membered heterocyclic ring containing 1, 2 or 3 heteroatoms selected from N, O, and S, wherein said heterocyclic ring or fused ring system is unsubstituted or substituted on a carbon or nitrogen atom; or a pharmaceutically acceptable salt thereof. 
pri čemu je "het" 5-7-člani heterociklički prsten koji sadrži 1-4 heteroatoma odabrana od N, O i S, ili 8-12-člani kondenzirani sustav prstena uključujući najmanje jedan 5-7-člani heterociklički prsten koji sadrži 1, 2 ili 3 heteroatoma odabrana od N, O i S, gdje je spomenuti heterociklički prsten ili kondenzirani sustav prstena nesupstituiran ili supstituiran na atomu ugljika ili dušika; ili njihove farmaceutski prihvatljive soli.
A compound of formula (IV) as claimed in claim 1 or claim 2, wherein wherein D is N(Rh), and Ar1 and Ar2 are substituted or unsubstituted phenyl or het, wherein said het is substituted or unsubstituted triazine, pyrimidine, pyridine, oxazol, 2,4-difluorophenyl, Cl-phenyl or fluorophenyl. 
Spojevi formule (IV) prema zahtjevu 1 ili 2, naznačeni time, da D je N(Rh), a Ar1 i Ar2 su supstituiran ili nesupstituiran fenil ili het, gdje je spomenuti het supstituiran ili nesupstituiran triazin, pirimidin, piridin, oksazol, 2,4-difluorofenil, Cl-fenil ili fluorofenil.
A compound of formula (IV) as claimed in claim 1 or claim 6, wherein D is C(O), and Ar1 and Ar2 are substituted or unsubstituted phenyl or het, wherein said het is substituted or unsubstituted oxazole, thiazole and oxadiazole. 
Spojevi formule (IV) prema zahtjevu 1 ili 6, naznačeni time, da D je C(O), a Ar1 i Ar2 su supstituiran ili nesupstituiran fenil ili het, gdje je spomenuti het supstituiran ili nesupstituiran oksazol, tiazol ili oksadiazol.
Use as claimed in claim 11, wherein the proliferative disease is a tumour. 
Uporaba prema zahtjevu 11, naznačena time, da proliferativna bolest je tumor.
Use as claimed in claim 11 or claim 12, wherein the proliferative disease is a selected from breast cancer, genitourinary cancer, lung cancer, gastrointestinal cancer, epidermoid cancer, melanoma, ovarian cancer, pancreas cancer, neuroblastoma, head and/or neck cancer, bladder cancer, renal, brain or gastric cancer, a mouth tumor, a lung tumor, colorectal tumor, prostate tumor and multiple myeloma. 
Uporaba prema zahtjevu 11 ili 12, naznačena time, da je proliferativna bolest odabrana od sljedećih: rak dojke, urogenitalni rak, rak pluća, gastrointestinalni rak, epidermalni rak, melanom, rak jajnika, rak gušterače, neuroblastom, rak glave i/ili vrata, rak mjehura, renalni ili gastrički rak, rak mozga, tumor usta, plućni tumor, kolorektalni tumor, tumor prostate i multipli mijelom.
A compound of formula (I) wherein ring B and the pyrimidine to which it is fused form a ring system selected from wherein 
Spoj sa formulom (I) [image] naznačen time da prsten B i pirimidin na koji je kondenziran tvore prstenasti sustav odabran od [image] pri čemu
is 1-4C-alkyl, 1-4C-alkoxy or halogen, or a salt, particularly a pharmaceutically acceptable salt, a tautomer, or a stereoisomer of said compound, or a salt, particularly a pharmaceutically acceptable salt, of said tautomer or said stereoisomer. 
je 1-4C-alkil, 1-4C-alkoksi ili halogen, ili sol, naročito farmaceutski prihvatljiva sol, tautomer, ili stereoizomer navedenog spoja, ili sol, naročito farmaceutski prihvatljiva sol navedenog tautomera ili navedenog stereoizomera.
The compound according to claim 1, wherein ring B and the pyrimidine to which it is fused form a ring system selected from wherein 
Spoj prema zahtjevu 1, naznačen time da prsten B i pirimidin na koji je kondenziran tvore prstenasti sustav odabran od [image] pri čemu
The compound according to claim 1, 2 or 3 wherein ring B and the pyrimidine to which it is fused form a ring system selected from wherein 
Spoj prema zahtjevu 1, 2 ili 3 naznačen time da prsten B i pirimidin na koji je kondenziran tvore prstenasti sustav odabran od [image] pri čemu
or a salt, particularly a pharmaceutically acceptable salt, a tautomer, or a stereoisomer of said compound, or a salt, particularly a pharmaceutically acceptable salt, of said tautomer or said stereoisomer. 
ili sol, naročito farmaceutski prihvatljiva sol, tautomer, ili stereoizomer navedenog spoja, ili sol, naročito farmaceutski prihvatljiva sol navedenog tautomera ili navedenog stereoizomera.
The use of a compound, or a tautomer of said compound, or a stereoisomer of said compound or a pharmaceutically acceptable salt of said compound, tautomer or stereoisomer according to any of claims 1 to 5 for the production of a pharmaceutical composition for the treatment of benign and/or malignant neoplasia. 
Uporaba spoja, ili tautomera navedenog spoja, ili stereoizomera navedenog spoja ili farmaceutski prihvatljive soli navedenog spoja, tautomera ili stereoizomera prema bilo kojem zahtjevu od 1 do 5 naznačena time da je za proizvodnju farmaceutskog pripravka za liječenje benignih i/ili malignih neoplazija.
The use of a compound, or a tautomer of said compound, or a stereoisomer of said compound or a pharmaceutically acceptable salt of said compound, tautomer or stereoisomer according to any of claims 1 to 5 for the production of a pharmaceutical composition for the treatment of cancer. 
Uporaba spoja, ili tautomera navedenog spoja, ili stereoizomera navedenog spoja ili farmaceutski prihvatljive soli navedenog spoja, tautomera ili stereoizomera prema bilo kojem zahtjevu od 1 do 5 naznačena time da je za proizvodnju farmaceutskog pripravka za liječenje raka.
A compound represented by Formula (I) or a salt thereof: wherein R1 represents the formula -A11-A12; 
Spoj prikazan sa formulom (I) ili njegova sol: [image] naznačen time da predstavlja formulu -A11-A12;
represents tetrahydrofurylmethyl, tetrahydropyranylmethyl or tetrahydropyranyl; A11 represents a single bond, methylene or 1,2-ethylene; 
predstavlja tetrahidrofurilmetil, tetrahidropiranilmetil ili tetrahidropiranil; A11 predstavlja jednostruku vezu, metilen ili 1,2-etilen;
A therapeutic or prophylactic agent comprising a compound according to any of Claims 1-13 for use in the treatment or prevention of depression, depressive symptoms, anxiety, irritable bowel syndrome, sleep disorder, insomnia, alcohol dependence, alcohol withdrawal symptoms, drug dependence, drug withdrawal symptoms, stress-related gastrointestinal dysfunction, anorexia nervosa, eating disorder, postoperative ileus, ischemic neuropathy, apoplexy, excitotoxic neuropathy, convulsion, epilepsy, hypertension, schizophrenia, bipolar disorder or dementia. 
Terapeutsko ili profilaktičko sredstvo koje sadrži spoj prema bilo kojem od zahtjeva 1-13 naznačeno time da je za uporabu kod liječenja ili sprečavanja depresije, simptoma depresije, tjeskobe, sindroma iritabilnog crijeva, poremećaja spavanja, nesanice, ovisnosti o alkoholu, simptoma odvikavanja od alkohola, ovisnosti o drogama, simptoma odvikavanja od droga, probavnih poremećaja vezanih uz stres, anoreksije, poremećaja prehrane, postoperativnog ileusa, ishemijske neuropatije, apopleksije, ekscitotoksične neuropatije, konvulzija, epilepsije, hipertenzije, shizofrenije, bipolarnog poremećaja ili demencije.
A therapeutic or prophylactic agent for use according to Claim 15, wherein the therapeutic or prophylactic agent is for use in the treatment or prevention of depression, depressive symptoms, anxiety or irritable bowel syndrome. 
Terapeutsko ili profilaktičko sredstvo za uporabu prema zahtjevu 15, naznačeno time da terapeutsko ili profilaktičko sredstvo je za uporabu kod liječenja ili sprečavanja depresije, simptoma depresije, tjeskobe ili sindroma iritabilnog crijeva.
A compound according to any of Claims 1-13 for use in the treatment or prevention of depression, depressive symptoms, anxiety, irritable bowel syndrome, sleep disorder, insomnia, alcohol dependence, alcohol withdrawal symptoms, drug dependence, drug withdrawal symptoms, stress-related gastrointestinal dysfunction, anorexia nervosa, eating disorder, postoperative ileus, ischemic neuropathy, apoplexy, excitotoxic neuropathy, convulsion, epilepsy, hypertension, schizophrenia, bipolar disorder or dementia. 
Spoj prema bilo kojem od zahtjeva 1-13 naznačen time da je za uporabu kod liječenja ili sprečavanja depresije, simptoma depresije, tjeskobe, sindroma iritabilnog crijeva, poremećaja spavanja, nesanice, ovisnosti o alkoholu, simptoma odvikavanja od alkohola, ovisnosti o drogama, simptoma odvikavanja od droga, probavnih poremećaja vezanih uz stres, anoreksije, poremećaja prehrane, postoperativnog ileusa, ishemijske neuropatije, apopleksije, ekscitotoksične neuropatije, konvulzija, epilepsije, hipertenzije, shizofrenije, bipolarnog poremećaja ili demencije.
A compound for use according to Claim 17, wherein the compound is for use in the treatment or prevention of depression, depressive symptoms, anxiety or irritable bowel syndrome. 
Spoj za uporabu prema zahtjevu 17, naznačen time da je spoj za uporabu kod liječenja ili sprečavanja depresije, simptoma depresije, tjeskobe ili sindroma iritabilnog crijeva.
A solid pharmaceutical dosage form for oral administration, after being constituted in water, comprising: 
Čvrsti farmaceutski dozirni oblik, naznačen time, da je za oralnu primjenu, nakon što se dobije u vodi, a sadrži:
a therapeutically effective amount of valganciclovir hydrochloride; and 
terapeutski učinkovitu količinu valganciklovir-hidroklorida; i
The solid dosage form according to claim 1, wherein valganciclovir hydrochloride is present in an amount from about 10% to about 90%, by weight of the total composition. 
Čvrsti dozirni oblik prema zahtjevu 1, naznačen time, da je valganciklovir-hidroklorid prisutan u količini od oko 10 do oko 90 masenih % od ukupnog sastava.
The solid dosage form according to claim 1, further comprising an effective amount of a non-hygroscopic bulking agent. 
Čvrsti dozirni oblik prema zahtjevu 1, naznačen time, da nadalje sadrži učinkovitu količinu nehigroskopnog sredstva za povećanje obujma.
The solid dosage form according to claim 4, wherein the non-hygroscopic bulking agent is selected from the group consisting of mannitol and lactose. 
Čvrsti dozirni oblik prema zahtjevu 4, naznačen time, da je nehigroskopno sredstvo za povećanje obujma odabrano iz skupine koju čine manitol i laktoza.
The solid dosage form according to claims 4 or 5, wherein the non-hygroscopic bulking agent is mannitol. 
Čvrsti dozirni oblik prema zahtjevu 4 ili 5, naznačen time, da nehigroskopno sredstvo za povećanje obujma je manitol.
The solid dosage form according to claims 4 to 6, wherein the non-hygroscopic bulking agent is present in an amount up to about 90% by weight of the total composition. 
Čvrsti dozirni oblik prema zahtjevima 4 do 6, naznačen time, da je nehigroskopno sredstvo za povećanje obujma prisutno u količini od oko 90 masenih % od ukupnog sastava.
The solid dosage form according to claims 1 to 7, wherein the dosage form has the following composition: Components 
Čvrsti dozirni oblik prema zahtjevima 1 do 7, naznačen time, da dozirni oblik ima sljedeći sastav:
A pharmaceutical composition comprising, as active ingredient, an effective amount of a compound of claim 1, optionally together with a pharmaceutically acceptable carrier. 
Farmaceutski sastav, naznačen time, da kao aktivni sastojak, obuhvaća učinkovitu količinu spoja prema zahtjevu 1, opcijski zajedno s farmaceutski prihvatljivim nosačem.
A pharmaceutical composition according to claim 8 or 9, which is in inhalable form. 
Farmaceutski sastav prema zahtjevu 8 ili zahtjevu 9, naznačen time, da je u obliku koji se može inhalirati.
A pharmaceutical composition according to claim 8, that further comprises as active ingredient one, two, three or more anti-inflammatory, bronchodilatory, antihistaminic/anti-allergic or anti-tussive drug substances. 
Farmaceutski sastav prema zahtjevu 8, naznačen time, da kao aktivni sastojak, nadalje obuhvaća jednu, dvije, tri ili više protuupalnih, bronhodilatornih, antihistaminskih/protualergijskih ili antitusivnih ljekovitih tvari.
A pharmaceutical composition according to claim 11, that further comprises as active ingredient one or both of mometasone furoate and glycopyrrolate. 
Farmaceutski sastav prema zahtjevu 11, naznačen time, da kao aktivni sastojak, nadalje obuhvaća jedan od spojeva ili oba spoja mometason furoata i glikopirolata.
for the preparation of compounds of formula I where A is acetate, reacting the free base with acetic acid; or 
reakciju slobodne baze s octenom kiselinom, za proizvodnju spojeva formule I, gdje A je acetat; ili
for the preparation of compounds of formula I where A is xinafoate, reacting the free base with 1-hydroxy-2-naphthoic acid. 
reakciju slobodne baze s 1-hidroksi 2-naftolnom kiselinom, za proizvodnju spojeva formule I, gdje A je ksinafoat.
R1' at each occurrence is independently selected from H, C1-C6 alkyl, C3-C7 cycloalkyl, C3-C10 aryl, arylalkyl; wherein said alkyl, aryl, arylalkyl groups are optionally substituted with one to three R20 groups; 
uvijek kada se pojavljuje je neovisno odabran od H, C1-C6 alkila, C3-C7 cikloalkila, C3-C10 arila, arilalkila; pri čemu navedene alkilna, arilna, arilalkilna skupine su proizvoljno supstituirane sa jednom do tri R20 skupine;
and R13 at each occurrence are each independently selected from H, C1-C6 alkyl, C6-C10 aryl, and NR23R24, or R12 and R13, together with the nitrogen to which they are attached, form a 3-7 membered heterocyclic ring; 
i R13 uvijek kada se pojavljuju su svaki neovisno odabrani od H, C1-C6 alkila, C6-C10 arila, i NR23R24, ili R12 i R13, zajedno sa dušikom na koji su spojeni, tvore 3-7 člani heterociklički prsten;
at each occurrence is independently selected from C1-C6 alkyl, C6-C10 aryl, and arylalkyl; wherein said alkyl, aryl and arylalkyl groups are optionally substituted with one to three groups R20 groups; 
uvijek kada se pojavljuje je neovisno odabran od C1-C6 alkila, C6-C10 arila, i arilalkila; pri čemu navedene alkilne, arilne i arilalkilne skupine su proizvoljno supstituirane sa jednom do tri R20 skupine;
at each occurrence is independently selected from H, C1-C8 alkyl, and C5-C10 aryl; wherein said alkyl and aryl groups are optional!y substituted with one to three R20 groups; 
uvijek kada se pojavljuje je neovisno odabran od H, C1-C8 alkila, i C5-C10 arila; pri čemu navedene alkilna i arilna skupina su proizvoljno supstituirane sa jednom do tri R20 skupine;
and R18 at each occurrence are each independently selected from H, C1-C5 alkyl and C6-C10 aryl, or R17 and R18, together with the nitrogen to which they are attached, form a 3-7 membered heterocyclic ring; 
i R18 uvijek kada se pojavljuju su svaki neovisno odabrani od H, C1-C5 alkila i C6-C10 arila, ili R17 i R18, zajedno sa dušikom na koji su spojeni, tvore 3-7 člani heterociklički prsten;
at each occurrence is independently selected from H, F, Cl, Br, C1-C6 alkyl, and C1-C8 alkyloxy; x is 1, 2, 3 or 4; comprising the steps of: 
uvijek kada se pojavljuje je neovisno odabran od H, F, Cl, Br, C1-C8 alkila, i C1-C8 alkiloksi; x je 1, 2, 3 ili 4; naznačen time da sadrži korake:
The method according to claim 23, wherein the oxidizing agent is cumene hydroperoxide. 
Postupak prema zahtjevu 23, naznačen time da oksidacijsko sredstvo je kumen hidroperoksid.
The method according to claim 26, wherein the crystallization is carried out in a mixture of an organic solvent with water. 
Postupak prema zahtjevu 26, naznačen time da se kristalizacija provodi u smjesi organskog otapala sa vodom.
The method according to claims 1 to 30 wherein the sulphoxide compound of formula (I) is obtained with an enantiomeric excess of at least 80 %. 
Postupak prema zahtjevima 1 do 30 naznačen time da je sulfoksid spoja sa formulom (I) dobiven sa enantiomernim viškom od barem 80 %.
A sulphoxide compound of formula (I) selected from: 
Sulfoksid spoja sa formulom (I) naznačen time da je odabran od:
Atomiser according to one of the preceding claims, characterised in that the container (3) during fluid extraction, fluid delivery, pressurisation and/or atomisation performs a preferably axial and/or stroke-like movement, in particular wherein the counter device (23) registers the movement of the container (3) or one of its end positions and counts this as an operation of the atomiser (1). 
Raspršivač prema jednom od prethodnih zahtjeva, naznačen time, da spremnik (3) poželjno izvršava aksijalno pomicanje i/ili pomicanje nalik na udar, za vrijeme izlučivanja tekućine, dostavljanja tekućine, stlačivanja i/ili raspršivanja, posebno za vrijeme dok uređaj za brojanje (23) zapisuje pomicanje spremnika (3) ili jedne od njegovih krajnjih pozicija i računa to kao jedno djelovanje raspršivača (1).
Atomiser according to one of the preceding claims, characterised in that the counter device (23) is adapted to count the number of operations performed or that can still be performed, in particular with the current container (3), by the atomiser (1) and preferably is adapted to displays this. 
Raspršivač prema jednom od prethodnih zahtjeva, naznačen time, da je uređaj za brojanje (23) namješten da broji količinu izvedenih djelovanja ili onih koja tek mogu biti izvedena, posebno s trenutačnim spremnikom (3), pomoću raspršivača (1) i poželjno je namješten da to prikazuje.
Atomiser according to claim 10, characterised in that the counter value is resettable manually or automatically when the container (3) is changed, in particular wherein the resetting is locked in the assembled state of the atomiser (1). 
Raspršivač prema zahtjevu 10, naznačen time, da se brojčana vrijednost može ponovno namjestiti ručno ili automatski kada se zamjenjuje spremnik (3), posebno dok je ponovno namještanje zaključano u sklopljenom stanju raspršivača (1).
Atomiser according to claim 19, characterised in that for changing the container (3) only the housing part (18) along with the container (3) and with the the first counter (31) is exchangeable. 
Raspršivač prema zahtjevu 19, naznačen time, da je prilikom zamjene spremnika (3), zamjenjiv samo dio kućišta (18) uz spremnik (3) te s prvim brojačem (31).